Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov:31 Suppl 26:17-19.
doi: 10.1111/pai.13340.

Type-2 inflammatory mediators as targets for precision medicine in children

Riccardo Castagnoli  1 , Amelia Licari  1 , Sara Manti  2 , Elena Chiappini  3 , Gian Luigi Marseglia  1
Affiliations

Type-2 inflammatory mediators as targets for precision medicine in children

Riccardo Castagnoli et al. Pediatr Allergy Immunol. 2020 Nov.

Abstract

The prevalence, heterogeneity, and severity of type 2 inflammatory diseases, including asthma and atopic dermatitis, continue to rise, especially in children and adolescents. Type 2 inflammation is mediated by both innate and adaptive immune cells and sustained by a specific subset of cytokines, such as interleukin (IL)-4, IL-5,IL-13, and IgE. IL-4 and IL-13 are considered signature type 2 cytokines, as they both have a pivotal role in many of the pathobiologic changes featured in asthma and atopic dermatitis. Several biologics targeting IL-4, IL-5, and IL-13, as well as IgE, have been proposed to treat severe allergic disease in the pediatric population with promising results. A better definition of type 2 inflammatory pathways is essential to implement targeted therapeutic strategies.

Keywords: asthma; atopic dermatitis; biologics; children; type 2 inflammation.

PubMed Disclaimer

References

REFERENCES

    1. Licari A, Castagnoli R, Marseglia A, et al. Dupilumab to treat type 2 inflammatory diseases in children and adolescents. Paediatr Drugs. 2020;22:295-310.
    1. Leonardi S, Vitaliti G, Marseglia GL, et al. Function of the airway epithelium in asthma. J BiolRegulHomeost Agents. 2012;26(1 Suppl):S41-S48.
    1. La Rosa M, Lionetti E, Leonardi S, et al. Specific immunotherapy in children: the evidence. Int J Immunopathol Pharmacol. 2011;24(4 Suppl):69-78.
    1. Ciprandi G, Marseglia GL, Castagnoli R, et al. From IgE to clinical trials of allergic rhinitis. Expert Rev Clin Immunol. 2015;11(12):1321-1333.
    1. Licari A, Manti S, Castagnoli R, et al. Targeted therapy for severe asthma in children and adolescents: current and future perspectives. Paediatr Drugs. 2019;21(4):215-237.